Intravenous Tirofiban Versus Alteplase Before Mechanical Thrombectomy in Stroke
ConditionStroke, Acute Ischemic
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorXinqiao Hospital of Chongqing
About this trial
In patients with acute ischemic stroke secondary to large vessel occlusion, the role of intravenous adjunctive medications, such as tirofiban, or alteplase before endovascular thrombectomy has not been well investigated. This trial aim to evaluate the efficacy and safety of intravenous tirofiban versus alteplase for acute ischemic stroke patients with large vessel occlusion piror to endovascular thrombectomy.
Eligibility criteria
Qualifiers
Aged 18 years or older.
Presenting with acute ischemic stroke symptom.
(1) within 4.5 hours
(2) 4.5-9.0 hours, image inclusion criteria for the EXTEND trial must be met
Disqualifiers
CT or MR evidence of hemorrhage (the presence of micro-bleeds is allowed);
Contraindications of IV rt-PA or tirofiban;
Contraindication to radiographic contrast agents, nickel, titanium metals or their alloys;
Arterial tortuosity and/or other arterial disease that would prevent the device from reaching the target vessel;
Trial design
Treatments tested in this trial
- Tirofiban
- Alteplase
Treatment groups
800 Participants
are divided into 2 treatment groupsSponsors and collaborators
Xinqiao Hospital of Chongqing
Lead sponsor
Zhejiang University
Collaborator
Source ClinicalTrials.gov